Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
05 mars 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 févr. 2024 16h01 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
29 janv. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
09 janv. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
03 janv. 2024 21h29 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Proposed Public Offering of Common Stock
03 janv. 2024 16h05 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
03 janv. 2024 08h00 HE
|
Keros Therapeutics, Inc.
Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report...
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
11 déc. 2023 06h00 HE
|
Keros Therapeutics, Inc.
KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in...
Keros Therapeutics to Present at Upcoming Healthcare Conferences
07 nov. 2023 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
06 nov. 2023 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...